CAS231277-92-2 The Lowest Price and Bulk Storage Peofessional Suppplier Lapatinib
|FOB Unit Price:||US $1 US $0.78|
|Purchase Qty. (g)||FOB Unit Price|
|Production Capacity:||2 Tons/Year|
|Transport Package:||1 Kg/Foil Bag|
|Payment Terms:||T/T, Western Union, Money Gram, Bitcoin|
- Model NO.: Lapatinib
- Customized: Customized
- Suitable for: Adult
- Purity: >99%
- Alias: Lapatinib
- Einecs No: C29h26clfn4o4s
- Molecular Weight: 581.0575432
- Trademark: YC
- Origin: Hubei, China
- Powder: Yes
- Certification: GMP, HSE, ISO 9001
- State: Solid
- Product Name: Lapatinib
- CAS Registry Number: 231277-92-2
- Molecular Formula: C29h26clfn4o4s
- Appearance: White Powder
- Specification: USD Standard
- HS Code: 3001200010
Product Name: Lapatinib
Synonyms: lapatinib;n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;Lapatinib(TINIBS);N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;Lapatinib Base N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
Product Categories: Molecular Targeted Antineoplastic;anti-neoplastic;Pharmaceutical intermediate;APIs;API;Lapatinib;Anti-cancer&immunity;Inhibitors
Mol File: 231277-92-2.mol
New drugs targeted therapy in breast cancer Lapatinib is developed by the British company GlaxoSmithKline,it is a breast cancer targeted therapy drug,it is a tyrosine kinase inhibitor, which can inhibit the human epidermal growth factor receptor-1 (ErbB1) and human epidermal growth factor receptor-2 (ErbB2) tyrosine kinase activity. It is unique because it can play a role in a variety of ways, so that the breast cancer cells can not receive the desired signal for the growth . The mechanism is inhibiting the ATP site of intracellular EGFR(ErbB-1) and HER2 (ErbB-2) to prevent phosphorylation and activation of tumor cells, blocking down signal by EGFR (ErbB-1) and homogenous HER2 (ErbB-1) and its heterodimer.
Breast cancer molecular targeted therapy aims at the occurrence and development of cancer-related genes and their expression products of breast cancer for treatment. Molecular targeted drugs by blocking signal transduction of tumor cells or associated cells , control changes in cell gene expression, in order to inhibit or kill tumor cells.
March 14, 2007, the US Food and Drug Administration approved lapatinib in combination with Xeloda (capecitabine) for the treatment of human epidermal factor receptor 2 (ErbB2) overexpression and treated by anthracyclines, paclitaxel and trastuzumab patients with advanced or metastatic breast cancer.
Clinical trials have shown that for those HER2 type breast cancer patients who are resistant to Roche's Herceptin , the product also has very good clinical results.
Lapatinib is a novel targeted anti-cancer drug. It Can act on Her-1 and Her-2 two targets at he same time, the biological effect of the inhibition of tumor cell proliferation and growth arising from this mode of action is much larger than acting on just one target. The so-called targeted therapy, refers to certain receptors, genes or proteins as a key target, and then targets to kill tumor cells related to drugs.
Human ErbB receptors belong to the type I receptor tyrosine kinase (TK) family. It includes ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). Cancer patients ErbB-1 (EGFR) and ErbB-2 (HER-2) receptors are usually over-expressed or other changes occur on them. Currently known human epidermal growth factor receptor-2 (ErbB-2, HER-2) is a clearer understanding human cancer gene which is closely related to breast cancer .its highly expression in breast cancer often precedes that it is easy to metastasize to lymph nodes and it is poorly differentiated , its prognosis is not good. With the in-depth study of HER-2 , it has become one target molecule of the breast cancer-specific therapy.
The above information is edited by the Chemicalbook of Tian Ye.
Usage Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
Usage Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
Usage antineoplastic, tyrosine kinase inhibitor
Wuhan Hengwo Scien-Tech Co., Ltd,is a leading supplier of raw steroids in China.We specialize in producing and seliing various kinds of
Raw steroid powders,semi-finished liquid injectable/oral steroids,polypeptide and natural hormones,Cortiscosteroids,progestational
hormones,etc.With High quality raw materials and advanced clean workshop,as well as strict quality control,our steroid hormones got many good feedback from all over the world.
Technique support is available whenever you have questions in making the steroid powders into finished products or when using.With over 14 years'
experiences exporting steroids worldwide,we have a high customs pass rate,also packages will be free resent to you in case it get seized."Delivery
guarantee,Quality service"is our promisr for you!
Let's join hand,go further and win together!